Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy

Published Date: 15 Jul 2024

A third of patients who had received multiple prior lines of therapy responded, small study shows

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

2.

The September 2018 issue of Medical Bulletin.

3.

10-year study shows tomosynthesis improves breast cancer detection

4.

Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP

5.

Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot